

REMARKS

By the present amendment, claims 1-19 and 22-28 are pending. Claims 20-21 have been cancelled without prejudice. Claims 3, 5, 9, 10-17 and 19 have been amended to eliminate multiple dependencies. Claims 2, 6, 7, 9-17 and 22-23 have been amended to more particularly and distinctly define Applicants' invention. New claims 24-28 have been added to more particularly and distinctly claim specific embodiments of the invention. Specifically, claims 24-25 have been added to specify types of osteonecrotic bone diseases. Claim 26 has been added to specify which disease or condition the side effects pertain to. Claim 27 has been added to specify particular anti-retroviral compounds. Claim 28 has been added to recite that the composition further comprises one or more pharmaceutically acceptable excipients.

No new matter has been added.

Applicant makes these amendments without prejudice to pursuing the original subject matter of this application in a later-filed application claiming benefit of the instant application, including without prejudice to any determination of equivalents of the claimed subject matter.

CONCLUSION

No additional fee is believed to be due with this Preliminary Amendment. Notwithstanding, should a fee be required, the Commissioner is authorized to charge the required fee to Jones Day Deposit Account No. 50-3013.

Date: August 24, 2005

Respectfully submitted,
By: *E. G. Meade*
Eric A. Meade Reg. No. 42,876
For: *Thomas G. Rowan*
Thomas G. Rowan (Reg. No. 34,419)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939